Abstract
Conventional treatment for metastatic bone pain requires a multidisciplinary approach (medical therapy, surgery, and radiation), but is primarily palliative. Biphosphonates introduced the concept of disease-modifying therapy, by effectively reducing bone pain and skeletal related events in patients suffering from bone metastatic cancer. In the past decade, the growing knowledge of bone biology and our understanding of the molecular mechanisms at the basis of the interaction between cancer cells and bone matrix led to the identification of new therapeutic targets for innovative “smart drugs”. The most investigated is the RANK/RANKL/OPG pathway, and denosumab, among novel targeted therapies, is the molecule that is in the most advanced development phase. Additional targets have been identified and potential novel therapeutic interventions, classified as inhibitors of bone resorption or stimulators of bone formation, are under preclinical and clinical evaluation. These promising targets include cathepsin K, the Src tyrosine kinases, integrins, chloride channels, the parathyroid hormone-related peptide, endotelin-1, sclerostin, and TGF-beta. Other pathways or molecules expressed by bone cells and cancer cells, such as CXCR4, GPNMB, EGF-family ligands, Wnt/DKK1, and MIP-1 alpha have recently emerged as potential targets. The aim of this review is to discuss the molecular mechanisms behind these emerging therapeutic targets in bone metastases and to give an overview of results from those in advanced clinical phases.
Keywords: Bone, Bone resorption, Cancer, Cathepsin K, CXCR4, Denosumab, ETAR, Metastasis, Molecular Targeted Therapy, Osteoclasts, Pain, RANKL, Skeletal Related Events, Src
Current Medicinal Chemistry
Title: Bone Metastatic Disease: Taking Aim at New Therapeutic Targets
Volume: 18 Issue: 20
Author(s): F. Coluzzi, E. Di Bussolo, I. Mandatori and C. Mattia
Affiliation:
Keywords: Bone, Bone resorption, Cancer, Cathepsin K, CXCR4, Denosumab, ETAR, Metastasis, Molecular Targeted Therapy, Osteoclasts, Pain, RANKL, Skeletal Related Events, Src
Abstract: Conventional treatment for metastatic bone pain requires a multidisciplinary approach (medical therapy, surgery, and radiation), but is primarily palliative. Biphosphonates introduced the concept of disease-modifying therapy, by effectively reducing bone pain and skeletal related events in patients suffering from bone metastatic cancer. In the past decade, the growing knowledge of bone biology and our understanding of the molecular mechanisms at the basis of the interaction between cancer cells and bone matrix led to the identification of new therapeutic targets for innovative “smart drugs”. The most investigated is the RANK/RANKL/OPG pathway, and denosumab, among novel targeted therapies, is the molecule that is in the most advanced development phase. Additional targets have been identified and potential novel therapeutic interventions, classified as inhibitors of bone resorption or stimulators of bone formation, are under preclinical and clinical evaluation. These promising targets include cathepsin K, the Src tyrosine kinases, integrins, chloride channels, the parathyroid hormone-related peptide, endotelin-1, sclerostin, and TGF-beta. Other pathways or molecules expressed by bone cells and cancer cells, such as CXCR4, GPNMB, EGF-family ligands, Wnt/DKK1, and MIP-1 alpha have recently emerged as potential targets. The aim of this review is to discuss the molecular mechanisms behind these emerging therapeutic targets in bone metastases and to give an overview of results from those in advanced clinical phases.
Export Options
About this article
Cite this article as:
Coluzzi F., Di Bussolo E., Mandatori I. and Mattia C., Bone Metastatic Disease: Taking Aim at New Therapeutic Targets, Current Medicinal Chemistry 2011; 18 (20) . https://dx.doi.org/10.2174/092986711796391660
DOI https://dx.doi.org/10.2174/092986711796391660 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immune Cells Act as Promising Targets for the Treatment of Bone Metastasis
Recent Patents on Anti-Cancer Drug Discovery Dendritic Cell-Based Immunotherapy in Thyroid Malignancies
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Denosumab: The Era of Targeted Therapies in Bone Metastatic Diseases
Current Cancer Drug Targets Open Questions on Bioequivalence: An Updated Reappraisal
Current Clinical Pharmacology Pregnancy, Programming and Preeclampsia: Gap Junctions at the Nexus of Pregnancy-induced Adaptation of Endothelial Function and Endothelial Adaptive Failure in PE
Current Vascular Pharmacology A Perspective on Stem Cells as Biological Systems that Produce Differentiated Osteoblasts and Odontoblasts
Current Stem Cell Research & Therapy Sweet on Hedgehogs: Regulatory Roles of Heparan Sulfate Proteoglycans in Hedgehog-Dependent Cell Proliferation and Differentiation
Current Protein & Peptide Science Recent Advances in Controlled Release Pulmonary Therapy
Current Drug Delivery Micronutrient Intake in the Etiology, Prevention and Treatment of Osteosarcopenic Obesity
Current Aging Science The Role of Proteomics in Osteoarthritis Pathogenesis Research
Current Drug Targets Editorial [Hot Topic:The Calcium-Sensing Receptor: Pathophysiology and Pharmacological Modulation(Guest Editor: Ubaldo Armato)]
Current Pharmaceutical Biotechnology ATF4, DLX3, FRA1, MSX2, C/EBP-ζ, and C/EBP-α Shape the Molecular Basis of Therapeutic Effects of Zoledronic Acid in Bone Disorders
Anti-Cancer Agents in Medicinal Chemistry Vitamin D, Sunlight and Cancer Connection
Anti-Cancer Agents in Medicinal Chemistry Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells
Current Cancer Drug Targets Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Role of Micronutrients on Subclinical Atherosclerosis Micronutrients in Subclinical Atherosclerosis
Current Pharmaceutical Design Medical Treatment of Primary, Secondary, and Tertiary Hyperparathyroidism
Current Drug Safety Advances and Barriers in Mammalian Cell Encapsulation for Treatment of Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Intracellular Signaling of the Aging Suppressor Protein Klotho
Current Molecular Medicine APE1/Ref-1Role in Redox Signaling: Translational Applications of Targeting the Redox Function of the DNA Repair/Redox Protein APE1/Ref-1
Current Molecular Pharmacology